LIXT Lixte Biotechnology Holdings, Inc. Total Debt to Capital

Lixte Biotechnology aims to expand its market presence by developing the LB-100 system to enhance chemotherapy, while the search for new treatments is accelerating through the implementation of bioinformatics algorithms. The asset's price trajectory demonstrates that the total debt-to-equity ratio is 0.13. The company is currently focusing on partnerships with medical centers to conduct tests, while eschewing merger deals.

This indicator compares total liabilities to net assets, determining the business's degree of dependence on borrowed funds when assessing financial stability. The current value of 0.13, within the context of fierce competition in oncopharmaceuticals, reflects the ability of Lixte Biotechnology (LIXT) to finance risky clinical developments, allowing the total debt-to-equity ratio to evaluate the company's margin of safety in the face of potential market failures.